Dr. Tandon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
303 E Chicago Ave
Chicago, IL 60611Phone+1 312-503-8223
Education & Training
UPMC Medical EducationFellowship, Hematopathology, 2012 - 2014
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 2008 - 2012
University of California (Irvine)Residency, Pathology-Anatomic and Clinical, 2008 - 2008
Eastern Virginia Medical SchoolClass of 2008
Certifications & Licensure
NY State Medical License 2016 - 2026
NJ State Medical License 2018 - 2025
GA State Medical License 2015 - 2023
TN State Medical License 2015 - 2022
KY State Medical License 2015 - 2021
SC State Medical License 2015 - 2021
NC State Medical License 2015 - 2020- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Pathology - Molecular Genetic
- American Board of Pathology Hematopathology
- Join now to see all
Publications & Presentations
PubMed
- 11 citationsAssociation of Li-Fraumeni Syndrome With Small Cell Carcinoma of the Ovary, Hypercalcemic Type and Concurrent Pleomorphic Liposarcoma of the CervixBevan Tandon, Ian S. Hagemann, Horacio M. Maluf, John D. Pfeifer, Hussam Al-Kateb
International Journal of Gynecological Pathology. 2017-11-01 - 23 citationsMutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Eric J. Duncavage, Geoffrey L. Uy, Allegra A. Petti, Christopher A. Miller, Yi-Shan Lee
Blood. 2017-03-09 - 583 citationsTP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesJohn S. Welch, Allegra A. Petti, Christopher A. Miller, Catrina Fronick, Michelle O'Laughlin
The New England Journal of Medicine. 2016-11-23
Press Mentions
OPKO Health’s BioReference Laboratories to Participate in the National Cancer Institute NCI-MATCH (Molecular Analysis for Therapy Choice) Phase II Clinical TrialAugust 28th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
